Ritratto di Loretta.Tuosto@uniroma1.it

Tutte le informazioni sui corsi e il relativo materiale didattico sono su e-learning.

 

Martedì 5 ottobre 2021 inizierà il corso di Oncologia Molecolare  in Aula 4 Fermi - Ed CU033 (Fisica) alle ore 14.00. l Corso si terrà tutti i martedì e giovedì dalle 14.00 alle 16.00 nella medesima aula.

Per partecipare alle lezioni in presenza è necessario avere il green pass e prenotare il posto in Aula seguendo le procedure indicate su: https://prodigit.uniroma1.it/prenotazioni/prenotaaule.nsf/home. Link Zoom: https://uniroma1.zoom.us/j/85222839951?pwd=Ymx4VFdKVVBTYUxPNXQxUmZOVUxGZz09

 

Martedì 1 marzo 2022 inizierà il corso di Immunologia in Aula Tatò - Ed RM024 alle ore 14.00. 

l Corso si terrà tutti i martedì e giovedì dalle 14.00 alle 16.00 nella medesima aula. Per partecipare alle lezioni in presenza è necessario avere il green pass e prenotare il posto in Aula seguendo le procedure indicate su: https://prodigit.uniroma1.it/prenotazioni/prenotaaule.nsf/home. Link Zoom: https://uniroma1.zoom.us/j/89612727473?pwd=UnZ0L3lxQWhFMkhiL0dxRVZYcFlSQT09

 

Mercoledì 2 marzo 2022 inizierà il corso di Immunopatologia delle Malattie Neurodegenerative in Aula B Tecce - Ed CU026 alle ore 14.00. 

l Corso si terrà tutti i lunedì e mercoledì dalle 14.00 alle 16.00 nella medesima aula. Per partecipare alle lezioni in presenza è necessario avere il green pass e prenotare il posto in Aula seguendo le procedure indicate su: https://prodigit.uniroma1.it/prenotazioni/prenotaaule.nsf/home. Link Zoom: https://uniroma1.zoom.us/j/83799257280?pwd=ZXcrN25TMFZwQUlhTlF2ZUdVekErUT09

 

 

Insegnamento Codice Anno Corso - Frequentare Bacheca
ONCOLOGIA MOLECOLARE 1023434 2021/2022
IMMUNOLOGIA 1019010 2021/2022
IMMUNOPATOLOGIA DELLE MALATTIE NEURODEGENERATIVE 10596044 2021/2022
ONCOLOGIA MOLECOLARE 1023434 2020/2021
IMMUNOPATOLOGIA DELLE MALATTIE NEURODEGENERATIVE 10596044 2020/2021
IMMUNOLOGIA 1019010 2020/2021
MOLECULAR ONCOLOGY 1051865 2019/2020
MECCANISMI CELLULARI E MOLECOLARI DELLA RISPOSTA IMMUNE 1047783 2019/2020
IMMUNOLOGIA 1019010 2019/2020
MOLECULAR ONCOLOGY 1051865 2018/2019
IMMUNOLOGIA 1019010 2018/2019
MECCANISMI CELLULARI E MOLECOLARI DELLA RISPOSTA IMMUNE 1047783 2018/2019
MECCANISMI CELLULARI E MOLECOLARI DELLA RISPOSTA IMMUNE 1047783 2017/2018
MOLECULAR ONCOLOGY 1051865 2017/2018
IMMUNOLOGIA 1019010 2017/2018
IMMUNOLOGIA 1019010 2016/2017
ONCOLOGIA MOLECOLARE 1023434 2016/2017

Martedì e Venerdì 10.00-12.00, I piano, via dei sardi 70, 00185 Roma


Abstracts in riviste scientifiche di classe A

Seminari

Riconoscimenti e premi

Appartenenza Società Scientifiche

Responsabilita' scientifica per progetti di ricerca internazionali e nazionali

Direzione o partecipazione a comitati editoriali di riviste

Citazioni e h- index

1. Tedeschi V, Paldino G, Paladini F, Mattorre B, Tuosto L, Sorrentino R, Fiorillo MT. The Impact of the 'Mis-Peptidome' on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response Int J Mol Sci. 2020 Dec 17;21(24):9608. doi: 10.3390/ijms21249608.

2. Kunkl M, Amormino C, Frascolla S, Sambucci M, De Bardi M, Caristi S, Arcieri S, Battistini L, Tuosto L. CD28 Autonomous Signaling Orchestrates IL-22 Expression and IL-22-Regulated Epithelial Barrier Functions in Human T Lymphocytes. Front Immunol. 2020 Oct 14;11:590964. doi: 10.3389/fimmu.2020.590964.

3. Bucci E., Andreev K., Bjorkman A., Calogero R. A., Carafoli E., Carninci P., Castagnoli P., Cossarizza A., Mussini C., Guerin P., Lipworth B., Sbardella G., Stocki T., Tuosto L., van Tulleken C., Viola A. Safety and efficacy of the Russian COVID-19 vaccine: more information needed. The Lancet, 2020 Oct 3;396(10256):e53. doi: 10.1016/S0140-6736(20)31960-7

4. Kunkl M, Sambucci M, Ruggieri S, Amormino C, Tortorella C, Gasperini C, Battistini L, Tuosto L. CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. Cells. 2019 Jun 11;8(6). pii: E575. doi: 10.3390/cells8060575.

5. Kunkl M, Mastrogiovanni M, Porciello N, Caristi S, Monteleone E, Arcieri S, Tuosto L. CD28 Individual Signaling Up-regulates Human IL-17A Expression by Promoting the Recruitment of RelA/NF- B and STAT3 Transcription Factors on the Proximal Promoter. Front Immunol. 2019 Apr 24;10:864. doi: 10.3389/fimmu.2019.00864. eCollection 2019

6. Tuosto L, Xu C. Editorial: Membrane Lipids in T Cell Functions. Front Immunol. 2018 Jul 9;9:1608. doi: 10.3389/fimmu.2018.01608.

7. Porciello N, Kunkl M, Tuosto L. CD28 between tolerance and autoimmunity: the side effects of animal models. F1000Res. 2018 May 30;7. pii: F1000 Faculty Rev-682. doi: 10.12688/f1000research.14046.1.

8. Porciello N, Grazioli P, Campese AF, Kunkl M, Caristi S, Mastrogiovanni M, Muscolini M, Spadaro F, Favre C, Nunès JA, Borroto A, Alarcon B, Screpanti I, Tuosto L. A non-conserved amino acid variant regulates differential signalling between human and mouse CD28. Nat Commun. 2018 Mar 14;9(1):1080. doi: 10.1038/s41467-018-03385-8.

9. Tuosto L. CD28. Encyclopedia of signalling molecules. 2018. pp 1-7. doi: 10.1007/978-1-4614-6438-9_101843-1

10. Kunkl M, Porciello N, Mastrogiovanni M, Capuano C, Lucantoni F, Moretti C, Persson JL, Galandrini R, Buzzetti R, Tuosto L. ISA-2011B, a Phosphatidylinositol 4-phosphate 5-kinase inhibitor, impairs CD28-dependent costimulatory and pro-inflammatory signals in human T lymphocytes. Front Immunol. 2017 Apr 26;8:502. doi: 10.3389/fimmu.2017.00502.

11. Porciello N, Kunkl M, Viola A, Tuosto L. Phosphatidylinositol 4-Phosphate 5-Kinases in the Regulation of T Cell Activation. Front Immunol. 2016 May 13;7:186. doi: 10.3389/fimmu.2016.00186.

12. Porciello N, Tuosto L. CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling. Cytokine Growth Factor Rev. 2016 Apr;28:11-9. doi: 10.1016/j.cytogfr.2016.02.004.

13. Kallikourdis M, Trovato AE, Roselli G, Muscolini M, Porciello N, Tuosto L*, Viola A. Phosphatidylinositol 4-phosphate 5-kinase controls recruitment of lipid rafts into the Immunological Synapse. J Immunol. 2016 Feb 15;196(4):1955-63 doi: 10.4049/jimmunol.1501788 (*corresponding author).

14. Tuosto L, Capuano C, Muscolini M, Santoni A, Galandrini R. The multifaceted role of PIP2 in leukocyte biology. Cell Mol Life Sci. 2015 Dec;72(23):4461-74 doi: 10.1007/s00018-015-2013-0.

15. Tuosto L. Targeting Inflammatory T Cells in Multiple Sclerosis: Current Therapies and Future Challenges. Austin J Mult Scler & Neuroimmunol. 2015;2(1): 1009.

16. Muscolini M, Camperio C, Porciello N, Caristi S, Capuano C, Viola A, Galandrini R, Tuosto L. Phosphatidylinositol 4-phosphate 5-kinase and Vav1 mutual cooperation in CD28-mediated actin remodeling and signaling functions. J Immunol. 2015 Feb 1;194(3):1323-33. doi: 10.4049/jimmunol.1401643. IF: 5.066

17. Colasanti T, Vomero M, Alessandri C, Barbati C, Maselli A, Camperio C, Conti F, Tinari A, Carlo-Stella C, Tuosto L, Benincasa D, Valesini G, Malorni W, Pierdominici M, Ortona E. Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. Cell Death Dis. 2014 May 29;5:e1265.

18. Camperio C., Muscolini M., Volpe E., Di Mitri D., Mechelli R., Buscarinu M.C., Ruggieri S., Piccolella E., Salvetti M., Gasperini C., Battistini L., Tuosto L. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunol Lett 2014 Jan 8;158(1-2):134-142 doi: 10.1016/j.imlet.2013.12.020.

19. Palermo V, Mangiapelo E, Piloto C, Pieri L, Muscolini M, Tuosto L, Mazzoni C. p53 death signal is mainly mediated by Nuc1(EndoG) in the yeast Saccharomyces cerevisiae. FEMS Yeast Res. 2013 Nov;13(7):682-8.

20. Muscolini M, Camperio C, Capuano C, Caristi S, Piccolella E, Galandrini R, Tuosto L. Phosphatidylinositol 4-phosphate 5-kinase activation critically contributes to CD28-dependent signaling responses. J Immunol. 2013 May 15;190(10):5279-86.

21. Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, Blandino G and Tuosto L. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J Biol Chem. 2011 Nov 18;286(46):39693-702.

22. Muscolini M., Sajeva A., Caristi S. and Tuosto L. A novel association between Filamin A and NF- B Inducing Kinase couples CD28 to Inhibitor of NF- B kinase and NF- B activation. Immunol Lett. 2011 May;136(2):203-12.

23. Tuosto L. NF- B family of transcription factors: Biochemical players of CD28 co-stimulation. Immunol Lett. 2011 Sep 21. Mar 30;135(1-2):1-9.

24. Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, Blandino G, Costanzo A, Sakaguchi K, Tuosto L. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. 2009 Oct 15;8(20):3396-405.

25. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, Tuosto L. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther. 2008 Jun;7(6):1410-9.

26. Annibaldi A, Sajeva A, Muscolini M, Ciccosanti F, Corazzari M, Piacentini M, Tuosto L. CD28 ligation in the absence of TCR promotes RelA/NF-kappaB recruitment and trans-activation of the HIV-1 LTR. Eur J Immunol. 2008 May;38(5):1446-51.

27. Falasca L, Farrace MG, Rinaldi A, Tuosto L, Melino G, Piacentini M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J Immunol. 2008 Feb 15;180(4):2616-24.

28. Cianfrocca R, Muscolini M, Marzano V, Annibaldi A, Marinari B, Levrero M, Costanzo A, Tuosto L. RelA/NF-kappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ. 2008 Feb;15(2):354-63.

29. Tavano R, Contento RL, Baranda SJ, Soligo M, Tuosto L, Manes S, Viola A. CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol. 2006 Nov;8(11):1270-6.

30. Scottà C, Tuosto L, Masci AM, Racioppi L, Piccolella E, Frasca L. Hypervariable region 1 variant acting as TCR antagonist affects hepatitis C virus-specific CD4+ T cell repertoire by favoring CD95-mediated apoptosis. J Leukoc Biol. 2005 Aug;78(2):372-82.

31. Tavano R, Gri G, Molon B, Marinari B, Rudd CE, Tuosto L, Viola A. CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes. J Immunol. 2004 Nov 1;173(9):5392-7.

32. Marinari B, Costanzo A, Marzano V, Piccolella E, Tuosto L. CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6098-103.

33. Marinari B, Simeoni L, Schraven B, Piccolella E, Tuosto L. The activation of Csk by CD4 interferes with TCR-mediated activatory signaling. Eur J Immunol. 2003 Sep;33(9):2609-18.

34. Guillaume S, Tuosto L, Tanchot C, Di Bartolo V, Acuto O, Rocha B. Proximal changes in signal transduction that modify CD8+ T cell responsiveness in vivo. Eur J Immunol. 2003 Sep;33(9):2551-6.

35. Tuosto L, Marinari B, Andreotti M, Federico M, Piccolella E. Vav exchange factor counteracts the HIV-1 Nef-mediated decrease of plasma membrane GM1 and NF-AT activity in T cells. Eur J Immunol. 2003 Aug;33(8):2186-96.

36. Piccolella E, Spadaro F, Ramoni C, Marinari B, Costanzo A, Levrero M, Thomson L, Abraham RT, Tuosto L. Vav-1 and the IKK alpha subunit of I kappa B kinase functionally associate to induce NF-kappa B activation in response to CD28 engagement. J Immunol. 2003 Mar 15;170(6):2895-903.

37. Tuosto L, Marinari B, Piccolella E. CD4-Lck through TCR and in the absence of Vav exchange factor induces Bax increase and mitochondrial damage. J Immunol. 2002 Jun 15;168(12):6106-12.

38. Marinari B, Costanzo A, Viola A, Michel F, Mangino G, Acuto O, Levrero M, Piccolella E, Tuosto L. Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur J Immunol. 2002 Feb;32(2):447-56.

39. Tuosto L, Parolini I, Schröder S, Sargiacomo M, Lanzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol. 2001 Feb;31(2):345-9.

40. Michel F, Mangino G, Attal-Bonnefoy G, Tuosto L, Alcover A, Roumier A, Olive D, Acuto O. CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation. J Immunol. 2000 Oct 1;165(7):3820-9.

41. Tuosto L, Costanzo A, Guido F, Marinari B, Vossio S, Moretti F, Levrero M, Piccolella E. Mitogen-activated kinase kinase kinase 1 regulates T cell receptor- and CD28-mediated signaling events which lead to NF-kappaB activation. Eur J Immunol. 2000 Sep;30(9):2445-54.

42. Somma F, Tuosto L*, Gilardini Montani MS, Di Somma MM, Cundari E, Piccolella E. Engagement of CD4 before TCR triggering regulates both Bax- and Fas (CD95)-mediated apoptosis. J Immunol. 2000 May 15;164(10):5078-87. (*co-first author).

43. Frasca L, Del Porto P, Tuosto L, Marinari B, Scottà C, Carbonari M, Nicosia A, Piccolella E. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J Immunol. 1999 Jul 15;163(2):650-8.

44. Gilardini Montani MS, Tuosto L, Giliberti R, Stefanini L, Cundari E, Piccolella E. Dexamethasone induces apoptosis in human T cell clones expressing low levels of Bcl-2. Cell Death Differ. 1999 Jan;6(1):79-86.

45. Michel F, Grimaud L, Tuosto L, Acuto O. Fyn and ZAP-70 are required for Vav phosphorylation in T cells stimulated by antigen-presenting cells. J Biol Chem. 1998 Nov 27;273(48):31932-8.

46. Tuosto L, Acuto O. CD28 affects the earliest signaling events generated by TCR engagement. Eur J Immunol. 1998 Jul;28(7):2131-42.

47. Viola A, Salio M, Tuosto L, Linkert S, Acuto O, Lanzavecchia A. Quantitative contribution of CD4 and CD8 to T cell antigen receptor serial triggering. J Exp Med. 1997 Nov 17;186(10):1775-9.

48. Mège D, Di Bartolo V, Germain V, Tuosto L, Michel F, Acuto O. Mutation of tyrosines 492/493 in the kinase domain of ZAP-70 affects multiple T-cell receptor signaling pathways. J Biol Chem. 1996 Dec 20;271(51):32644-52.

49. Tuosto L, Michel F, Acuto O. p95vav associates with tyrosine-phosphorylated SLP-76 in antigen-stimulated T cells. J Exp Med. 1996 Sep 1;184(3):1161-6.

50. Carbone E, Terrazzano G, Colonna M, Tuosto L, Piccolella E, Franksson L, Palazzolo G, Pérez-Villar JJ, Fontana S, Kärre K, Zappacosta S. Natural killer clones recognize specific soluble HLA class I molecules. Eur J Immunol. 1996 Mar;26(3):683-9.

51. Tuosto L, Piazza C, Moretti S, Modesti A, Greenlaw R, Lechler R, Lombardi G, Piccolella E. Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis. Eur J Immunol. 1995 Oct;25(10):2917-22.

52. Tuosto L, Gilardini Montani MS, Lorenzetti S, Cundari E, Moretti S, Lombardi G, Piccolella E. Differential susceptibility to monomeric HIV gp120-mediated apoptosis in antigen-activated CD4+ T cell populations. Eur J Immunol. 1995 Oct;25(10):2907-16.

53. Del Porto P, D'Amato M, Fiorillo MT, Tuosto L, Piccolella E, Sorrentino R. Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta T cell clone. J Immunol. 1994 Oct 1;153(7):3093-100.

54. Tuosto L, Karr RW, Fu XT, Olson RR, Cundari E, Piccolella E, Lechler R, Lombardi G. Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes. Hum Immunol. 1994 Aug;40(4):312-22.

55. Tuosto L, Cundari E, Gilardini Montani MS, Piccolella E. Analysis of susceptibility of mature human T lymphocytes to dexamethasone-induced apoptosis. Eur J Immunol. 1994 May;24(5):1061-5.

56. Carlucci S, Beschin A, Tuosto L, Ameglio F, Gandolfo GM, Cocito C, Fiorucci F, Saltini C, Piccolella E. Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Infect Immun. 1993 Feb;61(2):439-47. IF: 3.533

57. Gilardini Montani MS, Tuosto L, Delfini M, Guerritore D, Starace G, Politi E, Piccolella E. A new tripeptide, Pol 509, influences biochemical events associated with antigen presentation efficiency of PPD-specific EBV-B cells. Immunopharmacology. 1993 Jan-Feb;25(1):51-63. IF (2002): 4.202

1. Kunkl M, Mastrogivanni M, Porciello N, Caristi S, Monteleone E, Arcieri S, Tuosto L. ReIA/NF- B and STAT3 transcription factors cooperate in trans-activating the human IL-17A proximal promoter in response to CD28 individual stimulation. Eur J Immunol 2019 Sep: 49 (suppl 1): 181. 2nd Joint Meeting of the German-Society-for-Immunology (DGfl) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA), Sep 10-13 2019, Munich, Germany.

2. Kunkl M, Sambucci M, Ruggieri S, Amormino C, Caristi S, Gasperini C, Battistini L, Tuosto L. CD28 and associated class 1A P13K regulates the glycolytic metabolic program associated to pro-inflammatory T cell responses in Multiple Sclerosis. Eur J Immunol 2019 Sep: 49 (suppl 1): 188-189. 2nd Joint Meeting of the German-Society-for-Immunology (DGfl) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA), Sep 10-13 2019, Munich, Germany.

3. Tuosto L, Muscolini M, Camperio C, Caristi, S. Capuano C, Piccolella E, Galandrini, R. The recruitment and activation of phosphatidylinositol 4-phosphate 5-kinases critically regulate CD28-dependent signaling responses Front Immunol 2013 4: 1-1. 15th International Congress of Immunology ICI 2013, Aug 22-27 2013, Milano, Italia.

4. Tuosto L, Muscolini M, Montagni E, Palermo V, Caristi S, Mazzoni C, Di Agostino S, Blandino G, Gu W. The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein. Eur J Cancer 2012 Jul: 48 (suppl 5): S58. 22nd Biennial Congress of the European-Association-for-Cancer-Research, Jul 7-10 2012, Barcelona, Spain.

- Dal 1994 ha partecipato come relatore a diversi convegni scientifici in Italia e all'estero tra i quali: European Congress of Immunology (Barcellona 1994), Keystone Symposia (Keystone, Colorado, 1997), 2nd European Workshop on Cell Death (EWCD) - Apoptosis 2000, Gibilmanna, Sicilia (Aprile 2000), 3rd Lymphocyte signal transduction workshop, Aegean Conferences, Creta, Grecia (May 2005), 52nd Annual Meeting of the Italian Cancer Society, Roma (2010), 6th Lymphocyte signal transduction workshop, Aegean Conferences, Creta, Grecia (Giugno 2011). Joint Annual Meeting of Italian Society of Immunology, Clinical Immunology and Allergology (SIICA) and German Society for Immunology (DGfI) (Settembre 2011), 15th International Congress of mmunology (ICI), Milano (Agosto 2013).
- Chairman del workshop "Costimulation" al "15th International Congress of Immunology (ICI 2013)", Milano (22.08.2013 al 27.08.2013)
- Chairman del workshop "CELL SIGNALING AND TRANSCRIPTION FACTORS" al "IX National Conference of the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)", Firenze (28.05.2014 al 31.05.2014)
- Invited Lecture presso l Università di Wurzburg, Germania (14.01.2019)
- Invited Lecture (distanza) Università di Gerusalemme, Israele (17.12.2021)

- Premio PBI 1998, Gruppo di Cooperazione in Immunologia (GCI, 1998)
- 1° Premio "Mascia Brunelli", Associazione Italiana Colture Cellulari (ONLUS-AICC, 2000)
- Responsabile studi e ricerche scientifiche per l'Istituto Pasteur-Fondazione Cenci Bolognetti Roma (2008-ad oggi)
- Riconoscimento per l'eccellente contributo nella recensione di articoli scientifici per la rivista Cancer Letters (2016)
- Riconoscimento per l'eccellente contributo nella recensione di articoli scientifici per la rivista Cellular Signalling (2017)
- Vigevani Foundation Research Project Prize 2020 per ricerche congiunte Italia-Israele, con il Prof. Raymond Kaempefer, Faculty of Medicine, Hebrew University of Jerusalem.

- Socio della Società Italiana d Immunologia, Immunologia Clinica ed Allergologia (SIICA)
- Socio della European Cell Death Organization (ECDO)
- Socio della Federazione Europea di Immunologia (EFIS)

- Responsabile Progetto Giovani Ricercatori (MIUR, 2000), 18.000.000 lire
- Responsabile Progetto CNR-Agenzia 2000 (CNR, 2000), 23.000.000 Lire
- Responsabile di Unità di Ricerca, nell ambito del Programma di Ricerca Scientifica Interuniversitario (PRIN-2004), Coordinato dal Prof. Pasquale VITO , 61500 euro
- Responsabile di Unità di Ricerca, nell ambito del Programma di Ricerca Scientifica Interuniversitario (PRIN-2006), Coordinato dal Prof. Pasquale VITO, 60800 euro
- Responsabile di Unità di Ricerca del Progetto "Mechanisms and circumvention of chemotherapy resistance in ovarian cancer", Coordinato dal Prof. Salvatore MANCUSO, Grant Regionali AIRC (2005-2007), 64400 euro
- Responsabile del Progetto di Ateneo Federato Ricercatori "Caratterizzazione dell'attività pro-apoptotica di un nuovo mutante dell'oncosoppressore p53 (K351N) identificato in linee di carcinoma ovarico resistenti al cisplatino" Sapienza Università di Roma (2008), 10000 euro
- Responsabile del Progetto di Ateneo Federato "Caratterizzazione delle molecole di membrana e dei fattori trascrizionali coinvolti nel differenziamento e sopravvivenza dei linfociti T: ruolo della molecola costimolatoria CD28 e del citoscheletro" Sapienza Università di Roma (2009)
- Responsabile del Programma di Ricerca CD28 co-stimulatory molecule as a key regulator of T lymphocyte differentiation and survival: characterisation of the biochemical pathways and molecules coupling CD28 to NF- B activation Istituto-Pasteur-Fondazione cenci Bolognetti, Sapienza Università di Roma (2008-2010), 36000 euro
- Responsabile del Programma di Ricerca CD28 co-stimulatory molecule as a key regulator of NF- B signalling pathway: role of cytoskeleton in coupling CD28 to NF- B activation Istituto-Pasteur-Fondazione cenci Bolognetti, Sapienza Università di Roma (2011-2013), 60000 euro
- Responasabile del Progetto FISM 2011 "Characterization of CD28 signalling pathways as therapeutic targets to regulate immune tolerance in Multiple Sclerosis" Fondazione Italiana Sclerosi Multipla-FISM (2012-2013), 100000 euro
- Responsabile Progetto di Ateneo "Identification of CD28 associated signalling molecules as therapeutic targets in T cell leukaemia and lymphoma" Sapienza Università di Roma (2012), 7000 euro
- Responsabile Progetto di Ateneo "Characterization of the molecular mechanisms coupling CD28-dependent phospholipid turnover to the downstream signalling pathways regulating T lymphocyte functions" Sapienza Università di Roma (2013), 34946 euro
- Responsabile del Programma di Ricerca CD28 co-stimulatory molecule as a key regulator of NF- B signalling pathway: role of cytoskeleton in coupling CD28 to NF- B activation Istituto-Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma (2014-2017), 60000 euro
- Responsabile Progetto di Ateneo "Biochemical and functional characterization of PIP5K /Nck/Vav1 triple molecular complex in CD28-mediated actin cytoskeleton remodelling". Sapienza Università di Roma (2014), 5000 euro
- Responsabile Progetto di Ateneo "Characterization of the biochemical and functional differences between human and mouse CD28: role of a specific SH2 binding motif within the C-terminal proline rich motif of human CD28" Sapienza Università di Roma (2015), 8500 euro
- Responsabile Progetto di Ateneo "Characterization of a new inhibitory drug targeting CD28-associated PIP5K in regulating pro-inflammatory T cell responses" Sapienza Università di Roma (2016), 15000 euro
- Responsabile del Progetto FISM 2016 " Role of CD28 and associated class 1A PI3K in the regulation of the cellular metabolic programs associated to pro-inflammatory T cell responses in Multiple Sclerosis" Fondazione Italiana Sclerosi Multipla-FISM (2017-2019), 100000 euro
- Responsabile Progetto di Ateneo Role of CD28 and associated class 1A PI3K in the regulation of the cellular metabolic programs associated to pro inflammatory T cell responses Sapienza Università di Roma (2017), 14000 euro
- Responsabile del progetto di ricerca "Role of IL-6 and NF- B signalling mediators in CD28-induced IL-17A gene expression and Th17 cell subset expansion", Ricerche UNIVERSITARIE, Sapienza Università di Roma (2018), 33800 euro
- Responsabile del Programma di Ricerca Characterization of the signalling molecules and cellular metabolic programs regulating CD28 pro-inflammatory functionsn Istituto Pasteur Italia-Fondazione cenci Bolognetti, Sapienza Università di Roma (2019), 40000 euro
- Responsabile del Progetto di ricerca " Role of CD28 and associated class 1A PI3K in the regulation of IL-22 production and IL-22-producing T cell amplification", Ricerche UNIVERSITARIE, Sapienza Università di Roma (2019), 13500 euro
- Responsabile del progetto di Ricerca Characterization of the signalling motifs of human CD28 involved in the lethal inflammatory responses to bacterial superantigen toxins , Ricerche UNIVERSITARIE, Sapienza Università di Roma (2020), 1100 euro

- Dal 2000 è reviewer di diverse riviste scientifiche tra le quali: - Nature Review in Immunology - Journal of Immunology - British Journal of Immunology - BMC Immunology -Molecular Cancer Therapeutics European Journal of Immunology - Apoptosis Immunology Letters - Cell Death and Differentiation - Cancer Letters - Cell Death and Disease - Journal of Leukocyte Biology
- Associate Editor "American Journal of Clinical and Experimental Immunology"
- Associate Editor "Frontiers in Immunology": 49 edited pubblications e 1 Reserach Topic
- F1000 Faculty member: 29 article recommendations
- Revisore per progetti Nationali e Internazionali: MIUR (FIRB, 2013); ANFR (French National Research Agency, 2013); National Science Center (Cracovia, Polonia, 2016); EEA Grants Collaborative Research Projects (Romania, 2018); POR FSE 2014/2020, Friuli Venezia Giulia, 2019

Scopus: citazioni 1935, h-index 25

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali